AntriaBio, Inc. announced that it has closed a $2.7 million bridge note financing in an exempt private placement transaction with a number of accredited investors. Paulson Investment Company, Inc. served as the Company's sole placement agent in the transaction. The Company plans on raising additional funds in a private placement transaction in the first quarter of 2014 as it prepares for clinical studies for its lead product candidate, AB101, a proprietary, microsphere formulation of insulin that has the potential to be administered once per week and transform the treatment paradigm in the more than $8 billion a year basal insulin market.

The Bridge Financing will be used for general corporate purposes including the establishment of a cGMP manufacturing facility in the greater Denver, Colorado area.